MyFinsight
Home
Blog
About
Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc. (SER)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$1,502K
Free Cash flow
-$6,712K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Stock-based compensation
Non-cash interest expense
Others
Negative Cash Flow Breakdown
Accounts payable
Change in fair value of liabilit...
Prepaid expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-6,356
-6,898
-3,336
-4,595
Depreciation and amortization
18
18
24
16
Loss on disposal of property and equipment
-
-
-91
-
Non-cash lease expense
51
56
32
55
Non-cash interest expense
126
125
138
0
Amortization of debt issuance costs
77
64
58
0
Stock-based compensation
1,051
1,077
948
999
Common stock issued to consultant for services rendered
0
-
120
46
Restricted stock units released to consultant for services rendered
0
-
0
0
Change in fair value of convertible promissory notes
-
-
0
0
Change in fair value of warrants liabilities
-
-
-3,187
-1,076
Gain on warrants expiration
-
-
0
724
Loss on sale of subsidiary
-
-
-166
-
Change in fair value of liability classified instruments
-397
-1,134
-
-
Grant receivable
-
-
0
0
Loss on extinguishment of financial commitment assets and contingent warrants, net
0
-1,616
-
-
Prepaid expenses and other current assets
164
500
143
-766
Accounts payable
-967
896
-811
1,045
Accrued expenses
-49
162
67
-183
Operating lease liabilities
-51
-56
-32
-50
Increase (decrease) in other current liabilities
-23
6
-168
-182
Net cash used in operating activities
-6,684
-4,568
-6,033
-3,850
Purchase of equipment
28
25
0
13
Net cash used in investing activities
-28
-25
0
-13
Proceeds from the issuance of common stock and warrants to juvenescence
-
-
0
-
Drawdown on loan facilities from juvenescence
-
-
0
0
Cash and restricted cash acquired in connection with the merger
-
-
0
0
Proceeds from the exercise of post-merger warrants by juvenescence
-
-
0
0
Proceeds from the exercise of stock options
1
8
5
8
Proceeds from issuance of common stock-Juvenescence
0
0
0
0
Principal repayment on loan facilities to juvenescence
-
-
0
0
Principal repayments on finance lease liabilities
-
-
0
0
Proceeds from issuance of series a convertible preferred stock, net
0
-
0
0
Proceeds from issuance of common stock-At The Market Offering Program
-
-
476
1,523
Proceeds from issuance of common stock-At The Market Sales Agreement
0
10,169
-
-
Proceeds from 2025 convertible note, net
-
-
0
4,913
Proceeds from issuance of common stock and warrants in connection with private placement, net-Private Placement
5,201
15,880
-
-
Net cash provided by financing activities
5,202
26,057
481
6,444
Effect of foreign currency on cash
8
6
-12
-2
Net increase in cash and cash equivalents
-1,502
21,470
-5,564
2,579
At beginning of the period
24,526
3,056
8,620
3,672
At end of the period
23,024
24,526
3,056
8,620
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock and...
$5,201K
Proceeds from the
exercise of stock options
$1K
(-50.00%↓ Y/Y)
Net cash provided by
financing activities
$5,202K
(-50.40%↓ Y/Y)
Effect of foreign
currency on cash
$8K
Net increase in cash
and cash...
-$1,502K
(-163.40%↓ Y/Y)
Canceled cashflow
$5,210K
Stock-based compensation
$1,051K
(-43.07%↓ Y/Y)
Non-cash interest
expense
$126K
Amortization of debt issuance
costs
$77K
Non-cash lease expense
$51K
(-56.03%↓ Y/Y)
Depreciation and
amortization
$18K
(-45.45%↓ Y/Y)
Net cash used in
operating activities
-$6,684K
(17.20%↑ Y/Y)
Canceled cashflow
$1,323K
Net cash used in
investing activities
-$28K
(39.13%↑ Y/Y)
Net loss
-$6,356K
(43.67%↑ Y/Y)
Accounts payable
-$967K
(-200.42%↓ Y/Y)
Change in fair value of
liability classified...
-$397K
Prepaid expenses and
other current assets
$164K
(428.00%↑ Y/Y)
Operating lease
liabilities
-$51K
(51.43%↑ Y/Y)
Accrued expenses
-$49K
(57.39%↑ Y/Y)
Increase (decrease) in
other current...
-$23K
(-106.25%↓ Y/Y)
Purchase of equipment
$28K
(-39.13%↓ Y/Y)
Buy us a coffee